Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (161-170 of 218) with videos related to

Pageof 22
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesRicarda Rauschenberg, Johannes Bruns, Julia Brütting, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomasPhilipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibJan C Brase, Robert F H Walter, Alexander Savchenko, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Characterisation and outcome of RAC1 mutated melanomaGeorg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaGeorg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Pageof 22

Showing results (161-170 of 218) with videos related to

Sort By:
Pageof 22
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesRicarda Rauschenberg, Johannes Bruns, Julia Brütting, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomasPhilipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibJan C Brase, Robert F H Walter, Alexander Savchenko, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Characterisation and outcome of RAC1 mutated melanomaGeorg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaGeorg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Journal for Immunotherapy of Cancer|October 23, 2020
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patientsUlrike Leiter, Carmen Loquai, Lydia Reinhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOGSarah Knispel, Andreas Stang, Lisa Zimmer, et al.
Pageof 22